The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...

Novo Nordisk launched Ozempic in India on Friday—and the weight-loss drug will sell at a massive discount there, compared with U.S. prices. Novo is selling the 0.25 mg dose at 8,800 rupees ($97.27), ...

Novo Nordisk has had a difficult year: a tumbling stock price resulting in the biggest leadership shakeup in the company's ...

Canadians face a longer-than-expected wait for cheaper versions of Novo Nordisk A/S’s diabetes drug Ozempic after two of the ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, reflecting the company’s effort to capture two massive but different patient ...

GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight. But they need to be taken for years, ...

The pre-filled pen, which consists of four doses of 0.25mg injection required for initiation, costs Rs.8800 per month (Rs,2200 per week), 0.5 mg per month costs Rs.10,170 (Rs.2542.5 per week) and 1mg ...

Novo Nordisk A/S (NYSE: NVO) is making headlines as a leading player in the weight-loss drug market, primarily due to its blockbuster medications, Ozempic and Wegovy. With projected sales reaching $17 ...

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

Medications like Ozempic mimic a naturally occurring hormone called glucagon-like peptide-1, or GLP-1, which helps regulate ...

On Friday, Novo Nordisk A/S' (NYSE: NVO) board director Mikael Dolsten said he will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025.